Shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the seventeen research firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and fourteen have assigned a buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $35.8462.
A number of research firms have issued reports on DNLI. UBS Group boosted their target price on shares of Denali Therapeutics from $25.00 to $34.00 and gave the company a “buy” rating in a research note on Friday, August 7th. BTIG Research reaffirmed a “buy” rating and set a $39.00 price target on shares of Denali Therapeutics in a report on Monday, May 11th. Morgan Stanley boosted their price objective on Denali Therapeutics from $35.00 to $36.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. B. Riley Financial increased their price objective on Denali Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, August 25th. Finally, Wall Street Zen cut Denali Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday.
Read Our Latest Stock Analysis on Denali Therapeutics
Denali Therapeutics Stock Performance
Denali Therapeutics (NASDAQ:DNLI – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.17). The firm had revenue of $3.60 million for the quarter, compared to analyst estimates of $2.15 million. During the same period in the prior year, the company earned ($0.72) EPS. As a group, equities analysts anticipate that Denali Therapeutics will post -2.67 earnings per share for the current year.
Insider Activity
In other news, insider Alexander O. Schuth sold 2,857 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $25.07, for a total value of $71,624.99. Following the completion of the transaction, the insider owned 281,763 shares of the company’s stock, valued at approximately $7,063,798.41. This represents a 1.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 9.70% of the company’s stock.
Institutional Investors Weigh In On Denali Therapeutics
Institutional investors have recently bought and sold shares of the stock. Corient Private Wealth LP bought a new position in Denali Therapeutics in the 2nd quarter valued at about $301,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Denali Therapeutics during the 2nd quarter worth about $368,000. California State Teachers Retirement System raised its position in shares of Denali Therapeutics by 2,306.0% during the 2nd quarter. California State Teachers Retirement System now owns 3,911,652 shares of the company’s stock worth $100,608,000 after buying an additional 3,749,076 shares in the last quarter. Nykredit A S acquired a new stake in shares of Denali Therapeutics in the 2nd quarter worth approximately $38,000. Finally, Empowered Funds LLC acquired a new stake in shares of Denali Therapeutics in the 2nd quarter worth approximately $371,000. Institutional investors and hedge funds own 92.92% of the company’s stock.
About Denali Therapeutics
Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.
Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.
Featured Stories
- Five stocks we like better than Denali Therapeutics
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
